PRELUDE CAPITAL MANAGEMENT, LLC - IMMUNE DESIGN CORP ownership

IMMUNE DESIGN CORP's ticker is IMDZ and the CUSIP is 45252L103. A total of 60 filers reported holding IMMUNE DESIGN CORP in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of IMMUNE DESIGN CORP
ValueSharesWeighting
Q1 2019$193,000
+109.8%
32,983
+62.5%
0.01%
+83.3%
Q2 2018$92,000
+384.2%
20,302
+968.5%
0.01%
+200.0%
Q2 2017$19,000
+375.0%
1,900
+216.7%
0.00%
Q1 2017$4,0000.0%600
-11.9%
0.00%
Q4 2016$4,000
-42.9%
681
-14.9%
0.00%
-100.0%
Q2 2016$7,0008000.00%
Other shareholders
IMMUNE DESIGN CORP shareholders Q3 2016
NameSharesValueWeighting ↓
ProQuest Associates IV LLC 1,236,394$4,080,0004.69%
Versant Venture Management, LLC 2,208,210$7,287,093,0002.33%
EcoR1 Capital, LLC 4,437,600$14,422,0001.45%
BVF INC/IL 4,106,200$13,550,0001.37%
Abingworth LLP 352,300$1,145,0000.71%
DAFNA Capital Management LLC 328,500$1,084,0000.53%
Bain Capital Public Equity Management, LLC 1,680,987$5,547,0000.40%
Telemetry Investments, L.L.C. 248,800$821,0000.31%
Stonepine Capital Management, LLC 161,226$532,0000.28%
Focused Wealth Management, Inc 12,395$41,0000.01%
View complete list of IMMUNE DESIGN CORP shareholders